Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI (5-MeO-DMT)

This Phase I/II randomised, triple-blind, placebo-controlled trial (n=20) will study the effects of sublingual 5-MeO-DMT (6 mg, administered weekly for four weeks) on anxiety, depression, and cognitive function in individuals with mild to moderate Alzheimer’s disease.

The study, sponsored by Biomind Labs Inc., aims to assess whether 5-MeO-DMT can improve cognitive performance and alleviate emotional distress in patients with early-stage Alzheimer’s.

Participants, aged 40 to 80, must meet specific cognitive and psychological criteria, including moderate to high levels of anxiety and depression. Assessments will include neurocognitive tests, psychiatric evaluations, and biochemical markers to track cognitive and emotional changes over time. Safety measures, including cardiovascular monitoring and blood tests, will ensure participant well-being. The trial is being conducted in Argentina and will contribute to the growing evidence on the potential therapeutic benefits of psychedelics for neurodegenerative conditions.

Topic Anxiety Depression Healthy Subjects Neuroscience Neurocognitive Disorders
Compound 5-MeO-DMT Placebo
Country Argentina
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.